AI Quick Summary

🌍 Sironax expands into the Basel Area and announces $175M Novartis partnership.The Chinese biotech Sironax continues its international expansion by establishing its European subsidiary in the Basel Area, reinforcing its presence across Switzerland, Boston, and Australia.📍By joining the Switzerland Innovation Park Basel Area, Sironax becomes part of one of the world’s most vibrant life sciences ecosystems — home to breakthrough science, top-tier talent, and a uniquely collaborative environment.Why the Basel Area?💊 Global hub for life sciences and biomedical research🔬 Rich academic and clinical research infrastructure🌐 Seamless support for international growth🧭 Strategically located in the heart of EuropeAs part of this milestone, Sironax has also entered a $175M option deal with Novartis to co-develop therapies targeting the blood-brain barrier — a major step forward in treating neurological diseases.We’re proud to welcome Sironax to the region and our Main Campus, and look forward to supporting their innovation journey! 👏🔗 Learn more about the Main Campus: Main Campus - Switzerland Innovation Park Basel Area

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 8/19/2025 12:33:38 PM
• Modified Date: 8/19/2025 12:33:38 PM

Post Description

🌍 Sironax expands into the Basel Area and announces $175M Novartis partnership.

The Chinese biotech Sironax continues its international expansion by establishing its European subsidiary in the Basel Area, reinforcing its presence across Switzerland, Boston, and Australia.

📍By joining the Switzerland Innovation Park Basel Area, Sironax becomes part of one of the world’s most vibrant life sciences ecosystems — home to breakthrough science, top-tier talent, and a uniquely collaborative environment.

Why the Basel Area?

💊 Global hub for life sciences and biomedical research

🔬 Rich academic and clinical research infrastructure

🌐 Seamless support for international growth

🧭 Strategically located in the heart of Europe

As part of this milestone, Sironax has also entered a $175M option deal with Novartis to co-develop therapies targeting the blood-brain barrier — a major step forward in treating neurological diseases.

We’re proud to welcome Sironax to the region and our Main Campus, and look forward to supporting their innovation journey! 👏

🔗 Learn more about the Main Campus: Main Campus - Switzerland Innovation Park Basel Area